Literature DB >> 18220799

Emerging indications for statins: a pluripotent family of agents with several potential applications.

Kosmas I Paraskevas1, Alexandros A Tzovaras, Despina D Briana, Dimitri P Mikhailidis.   

Abstract

Statins are pluripotent agents exhibiting multiple non-lipid-lowering actions. Besides their established role in the management of hypercholesterolemia, statins may also have beneficial actions in other pathological conditions, namely: a) osteoporosis and osteoporosis-related bone fractures, b) cancer, c) solid organ transplantation, d) cerebrovascular events (transient ischemic attack and stroke episodes), e) various neurological disorders, such as Alzheimer's disease, Parkinson's disease and multiple sclerosis, f) cardiac arrhythmias and heart failure, g) renal diseases, h) rheumatoid arthritis, i) autoimmune diseases, j) sepsis, and k) allergic asthma. We reviewed the literature searching for studies that support or oppose the use of statins in each proposed indication. In some of these emerging indications, a role for statin treatment is more firmly set; for others, current evidence is more controversial. Future trials may reveal more convincing evidence that will make statin use necessary in the therapeutic management of several diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18220799     DOI: 10.2174/138161207782794194

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  24 in total

1.  Anti-Inflammatory Agents for Cancer Therapy.

Authors:  Elizabeth R Rayburn; Scharri J Ezell; Ruiwen Zhang
Journal:  Mol Cell Pharmacol       Date:  2009

2.  Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome.

Authors:  Patricia Redecha; Claus-Werner Franzke; Wolfram Ruf; Nigel Mackman; Guillermina Girardi
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

3.  Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma.

Authors:  Samuel D Kaffenberger; Opal Lin-Tsai; Kelly L Stratton; Todd M Morgan; Daniel A Barocas; Sam S Chang; Michael S Cookson; S Duke Herrell; Joseph A Smith; Peter E Clark
Journal:  Urol Oncol       Date:  2014-10-31       Impact factor: 3.498

4.  Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury.

Authors:  Patricia Redecha; Nico van Rooijen; Donald Torry; Guillermina Girardi
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

5.  Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.

Authors:  Nicola J Sinden; Robert A Stockley
Journal:  Ther Adv Chronic Dis       Date:  2010-03       Impact factor: 5.091

6.  Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins.

Authors:  Jean-Pierre H Perchellet; Elisabeth M Perchellet; Kyle R Crow; Keith R Buszek; Neil Brown; Sampathkumar Ellappan; Ge Gao; Diheng Luo; Machiko Minatoya; Gerald H Lushington
Journal:  Int J Mol Med       Date:  2009-11       Impact factor: 4.101

7.  Effect of preoperative statin therapy on myocardial protection and morbidity endpoints following off-pump coronary bypass surgery in patients with elevated C-reactive protein level.

Authors:  Young Song; Young Lan Kwak; Yong Seon Choi; Jong Chan Kim; Sang Baek Heo; Jae Kwang Shim
Journal:  Korean J Anesthesiol       Date:  2010-02-28

Review 8.  Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome.

Authors:  Guillermina Girardi
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

9.  HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy.

Authors:  Manuela Bartoli; Mohamed Al-Shabrawey; Mohamed Labazi; M Ali Behzadian; Mohamed Istanboli; Azza B El-Remessy; Robert W Caldwell; Dennis M Marcus; Ruth B Caldwell
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-12-20       Impact factor: 4.799

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.